We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04424316




Registration number
NCT04424316
Ethics application status
Date submitted
3/06/2020
Date registered
9/06/2020
Date last updated
8/04/2021

Titles & IDs
Public title
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Scientific title
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY
Secondary ID [1] 0 0
2019-002943-85
Secondary ID [2] 0 0
C3671008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Tract Infection 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - RSVpreF
Other interventions - Placebo

Experimental: RSVpreF vaccine - RSVpreF

Placebo Comparator: Placebo dose - Placebo


Other interventions: RSVpreF
RSV vaccine (RSVpreF)

Other interventions: Placebo
Placebo

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The percentage reduction in the incidence of medically attended LRTI (MA-LRTI) due to RSV in infants through 180 days of life - The percentage relative risk reduction in the incidence of MA-LRTI due to RSV in the RSV vaccine group, relative to the placebo group will be assessed at specified timepoints in infant participants
Timepoint [1] 0 0
Delivery to 180 days after delivery
Primary outcome [2] 0 0
The percentage reduction in the incidence of medically attended severe LRTI due to RSV in infants through 180 days of life - The percentage relative risk reduction in the incidence of severe MA-LRTI due to RSV in the RSV vaccine group, relative to the placebo group will be assessed at specified timepoints in infant participants
Timepoint [2] 0 0
Delivery to 180 days after delivery
Primary outcome [3] 0 0
The percentage of infant participants with specific birth outcomes - Describe specific birth outcomes for infant participants
Timepoint [3] 0 0
Birth
Primary outcome [4] 0 0
The percentage of infant participants with adverse events (AEs) from birth to 1 month of age - Describe AE for infant participants from birth to 1 month of age
Timepoint [4] 0 0
Up to 1 month of age
Primary outcome [5] 0 0
The percentage of infant participants with serious adverse events (SAE) and newly diagnosed chronic medical conditions (NDCMCs) from birth to 12 months of age - Describe SAE and NDCMCs for infant participants from birth to 12 months of age
Timepoint [5] 0 0
From birth up to 12 months of age
Primary outcome [6] 0 0
The percentage of infant participants with serious adverse events (SAE) and newly diagnosed chronic medical conditions (NDCMCs) from birth to 24 months of age - Describe SAE and NDCMCs for infant participants from birth to 24 months of age
Timepoint [6] 0 0
From birth up to 24 months of age
Primary outcome [7] 0 0
Percentage of maternal participants reporting local reactions and systemic events from day of vaccination (Day 1) until Day 7 - Describe local reactions and systemic events after vaccination
Timepoint [7] 0 0
From day of vaccination until 7 days after vaccination
Primary outcome [8] 0 0
Percentage of maternal participants reporting Adverse Events (AE) within 1 month after vaccination - Describe adverse events (AE) after vaccination
Timepoint [8] 0 0
Within 1 month after vaccination
Primary outcome [9] 0 0
Percentage of maternal participants reporting SAEs - Describe serious adverse events from enrolment up to 180 days after delivery
Timepoint [9] 0 0
From enrollment up to 180 days after delivery
Secondary outcome [1] 0 0
The percentage reduction in the incidence of hospitalizations due to RSV in infants through 180 days of life - The percentage relative risk reduction in the incidence of hospitalization due to RSV in the RSV vaccine group, relative to the placebo group will be assessed at specified timepoints in infant participants
Timepoint [1] 0 0
Delivery to 180 days after delivery
Secondary outcome [2] 0 0
The percentage reduction in the incidence of all-cause MA-LRTI in infant participants - The percentage relative risk reduction in the incidence of all-cause MA-LRTI in the RSV vaccine group, relative to the placebo group will be assessed at specified timepoints in infant participants
Timepoint [2] 0 0
Delivery to 180 days after delivery

Eligibility
Key inclusion criteria
Inclusion Criteria - Maternal Participants:

- Healthy women 18 to 49 years of age who are between 24 0/7 and 36 0/7 weeks of
gestation on the day of planned vaccination, with an uncomplicated, singleton
pregnancy, who are at no known increased risk for complications.

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other study procedures.

- Receiving prenatal standard of care based on country requirements.

- Had an ultrasound examination performed at =18 weeks of pregnancy with no significant
fetal abnormalities observed, based on the investigator's judgment.

- Determined by medical history, physical examination, and clinical judgment to be
appropriate for inclusion in the study.

- Documented negative HIV antibody test, syphilis test, and hepatitis B virus (HBV)
surface antigen test during this pregnancy and prior to randomization (Visit 1).

- Intention to deliver at a hospital or birthing facility where study procedures can be
obtained.

- Expected to be available for the duration of the study and can be contacted by
telephone during study participation.

- Participant is willing to give informed consent for her infant to participate in the
study.

- Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the informed consent document (ICD) and in
this protocol OR If the maternal participant is illiterate, a thumbprinted informed
consent must be obtained, which must be signed and dated by an impartial witness who
was present throughout the entire informed consent process confirming that the
maternal participant has been informed of all pertinent aspects of the study.

Inclusion Criteria -Infant Participants:

- Evidence of a signed and dated ICD signed by the parent(s)/legal guardian(s) OR If the
infant participant's maternal participant/parent(s)/legal guardian(s) is illiterate, a
thumbprinted informed consent must have been obtained, which must have been signed and
dated by an impartial witness who was present throughout the entire informed consent
process confirming that the maternal participant/parent(s)/legal guardian(s) has been
informed of all pertinent aspects of the study for herself (maternal participant) and
her fetus/infant prior to taking part in the study.

- Parent(s)/legal guardian(s) willing and able to comply with scheduled visits,
treatment plan, laboratory tests, and other study procedures.
Minimum age
11 Years
Maximum age
49 Years
Gender
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria - Maternal Participants:

- Prepregnancy body mass index (BMI) of >40 kg/m2. If prepregnancy BMI is not available,
the BMI at the time of the first obstetric visit during the current pregnancy may be
used.

- Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.

- History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the investigational product or any
related vaccine.

- Current pregnancy resulting from in vitro fertilization.

- Current pregnancy complications or abnormalities at the time of consent that will
increase the risk associated with the participation in and completion of the study,
including but not limited to the following:

- Preeclampsia, eclampsia, or uncontrolled gestational hypertension.

- Placental abnormality.

- Polyhydramnios or oligohydramnios.

- Significant bleeding or blood clotting disorder.

- Endocrine disorders, including untreated hyperthyroidism or untreated
hypothyroidism. This also includes disorders of glucose intolerance (eg, diabetes
mellitus type 1 or 2) antedating pregnancy or occurring during pregnancy if
uncontrolled at the time of consent.

- Any signs of premature labor with the current pregnancy or having ongoing
intervention (medical/surgical) in the current pregnancy to prevent preterm
birth.

- Prior pregnancy complications or abnormalities at the time of consent, based on the
investigator's judgment, that will increase the risk associated with the participation
in and completion of the study, including but not limited to the following:

- Prior preterm delivery =34 weeks' gestation.

- Prior stillbirth or neonatal death.

- Previous infant with a known genetic disorder or significant congenital anomaly.

- Major illness of the maternal participant or conditions of the fetus that, in the
investigator's judgment, will substantially increase the risk associated with the
maternal or infant participant's participation in, and completion of, the study or
could preclude the evaluation of the maternal participant's response (includes
positive serologic testing for regional endemic conditions assessed during routine
maternal care, as per local standards of care and obstetric recommendations).

- Congenital or acquired immunodeficiency disorder, or rheumatologic disorder or other
illness requiring chronic treatment with known immunosuppressant medications,
including monoclonal antibodies, within the year prior to enrollment.

- Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the participant inappropriate for entry into
this study.

- Participation in other studies involving investigational drug(s) within 28 days prior
to consent and/or during study participation.

- Receipt of monoclonal antibodies within the year prior to enrollment or the use of
systemic corticosteroids for >14 days within 28 days prior to study enrollment.
Prednisone use of <20 mg/day for =14 days is permitted. Inhaled/nebulized,
intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

- Current alcohol abuse or illicit drug use. Note: Marijuana use is not considered an
illicit drug for study eligibility.

- Receipt of blood or plasma products or immunoglobulin (Ig), from 60 days before
investigational product administration, or planned receipt through delivery, with 1
exception, Rho(D) immune globulin (eg, RhoGAM), which can be given at any time.

- Previous vaccination with any licensed or investigational RSV vaccine or planned

- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
Pfizer employees, including their family members, directly involved in the conduct of
the study.

- Participants who are breastfeeding at the time of enrollment.

Exclusion Criteria -Infant Participants:

o Infant who is a direct descendant (eg, child or grandchild) of the study personnel.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
Women's and Children's Hospital - North Adelaide
Recruitment hospital [2] 0 0
Monash Children's Hospital - Clayton
Recruitment hospital [3] 0 0
Barwon Health, University Hospital Geelong - Geelong
Recruitment postcode(s) [1] 0 0
5006 - North Adelaide
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3220 - Geelong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Kentucky
Country [14] 0 0
United States of America
State/province [14] 0 0
Louisiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Montana
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
Nevada
Country [23] 0 0
United States of America
State/province [23] 0 0
New Jersey
Country [24] 0 0
United States of America
State/province [24] 0 0
New Mexico
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oklahoma
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
South Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
Tennessee
Country [32] 0 0
United States of America
State/province [32] 0 0
Texas
Country [33] 0 0
United States of America
State/province [33] 0 0
Utah
Country [34] 0 0
United States of America
State/province [34] 0 0
Virginia
Country [35] 0 0
United States of America
State/province [35] 0 0
Washington
Country [36] 0 0
United States of America
State/province [36] 0 0
West Virginia
Country [37] 0 0
United States of America
State/province [37] 0 0
Wisconsin
Country [38] 0 0
Argentina
State/province [38] 0 0
Santa FE
Country [39] 0 0
Argentina
State/province [39] 0 0
Tucuman
Country [40] 0 0
Argentina
State/province [40] 0 0
Buenos Aires
Country [41] 0 0
Argentina
State/province [41] 0 0
Caba
Country [42] 0 0
Argentina
State/province [42] 0 0
Salta
Country [43] 0 0
Brazil
State/province [43] 0 0
RS
Country [44] 0 0
Brazil
State/province [44] 0 0
SC
Country [45] 0 0
Brazil
State/province [45] 0 0
SP
Country [46] 0 0
Canada
State/province [46] 0 0
Nova Scotia
Country [47] 0 0
Canada
State/province [47] 0 0
Quebec
Country [48] 0 0
Chile
State/province [48] 0 0
Región DE LOS Lagos
Country [49] 0 0
Chile
State/province [49] 0 0
Región Metropolitana
Country [50] 0 0
Denmark
State/province [50] 0 0
Aarhus N
Country [51] 0 0
Denmark
State/province [51] 0 0
Hillerod
Country [52] 0 0
Denmark
State/province [52] 0 0
Hvidovre
Country [53] 0 0
Denmark
State/province [53] 0 0
Odense C
Country [54] 0 0
Finland
State/province [54] 0 0
Helsinki
Country [55] 0 0
Finland
State/province [55] 0 0
Kokkola
Country [56] 0 0
Finland
State/province [56] 0 0
Oulu
Country [57] 0 0
Finland
State/province [57] 0 0
Pori
Country [58] 0 0
Finland
State/province [58] 0 0
Seinajoki
Country [59] 0 0
Finland
State/province [59] 0 0
Tampere
Country [60] 0 0
Finland
State/province [60] 0 0
Turku
Country [61] 0 0
Gambia
State/province [61] 0 0
Fajara, KMC
Country [62] 0 0
Japan
State/province [62] 0 0
Hyogo
Country [63] 0 0
Japan
State/province [63] 0 0
Kanagawa
Country [64] 0 0
Japan
State/province [64] 0 0
Kyoto
Country [65] 0 0
Japan
State/province [65] 0 0
MIE
Country [66] 0 0
Japan
State/province [66] 0 0
Miyagi
Country [67] 0 0
Japan
State/province [67] 0 0
Oita
Country [68] 0 0
Japan
State/province [68] 0 0
Okinawa
Country [69] 0 0
Japan
State/province [69] 0 0
Osaka
Country [70] 0 0
Japan
State/province [70] 0 0
Tokyo
Country [71] 0 0
Japan
State/province [71] 0 0
Saitama
Country [72] 0 0
Japan
State/province [72] 0 0
Shizuoka
Country [73] 0 0
Netherlands
State/province [73] 0 0
Hoofddorp
Country [74] 0 0
Netherlands
State/province [74] 0 0
Utrecht
Country [75] 0 0
New Zealand
State/province [75] 0 0
Auckland
Country [76] 0 0
New Zealand
State/province [76] 0 0
Christchurch
Country [77] 0 0
New Zealand
State/province [77] 0 0
Wellington
Country [78] 0 0
South Africa
State/province [78] 0 0
FREE State
Country [79] 0 0
South Africa
State/province [79] 0 0
Gauteng
Country [80] 0 0
South Africa
State/province [80] 0 0
Limpopo
Country [81] 0 0
South Africa
State/province [81] 0 0
Western CAPE
Country [82] 0 0
South Africa
State/province [82] 0 0
Cape Town
Country [83] 0 0
South Africa
State/province [83] 0 0
Worcester
Country [84] 0 0
Spain
State/province [84] 0 0
A Coruna
Country [85] 0 0
Spain
State/province [85] 0 0
Malaga
Country [86] 0 0
Spain
State/province [86] 0 0
Madrid
Country [87] 0 0
Spain
State/province [87] 0 0
Mostoles
Country [88] 0 0
Spain
State/province [88] 0 0
Valencia
Country [89] 0 0
Taiwan
State/province [89] 0 0
Hsinchu City
Country [90] 0 0
Taiwan
State/province [90] 0 0
Kaohsiung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taipei City
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taipei
Country [93] 0 0
Taiwan
State/province [93] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the
efficacy and safety of maternal immunization with RSVpreF against medically attended lower
respiratory tract illness (MA-LRTI) in infants.
Trial website
https://clinicaltrials.gov/show/NCT04424316
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
ClinicalTrials.gov_Inquiries@pfizer.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04424316